Listed.

The emergence of biosimilars not only promise to offer more affordable alternatives to established biological agents (oh hey again, bev) but may also prove to finally put a dent in the sticker shock with the so-called trade names. Across four biologics with biosimilars in the US marketplace, net pricing indeed decreased from 2007 to 2018. | San-Juan-Rodriguez, JAMA Nets Open 2019